The Oklahoman

Preventing clots

- Jim Stafford Jim Stafford writes about Oklahoma innovation and research and developmen­t topics on behalf of the Oklahoma Center for the Advancemen­t of Science & Technology. Go to oklahoman.com and enter the code to see a video at Compressio­n Solutions.

Compressio­n Solutions Inc. makes a device that helps patients recovering from surgery. It prevents blood clot developmen­t in the lower leg in deep vein thrombosis.

TULSA — What if two Boeing 747 jetliners crashed every day for a year, taking the lives of every passenger aboard? It’s a nightmare scenario that would be a disaster of unparallel­ed proportion­s.

Well, it turns out there is a medical condition that claims the lives of up to 300,000 Americans annually — the equivalent to two 747s crashing every single day for a year. And it rarely receives a headline.

The condition is known as deep vein thrombosis (DVT), which develops when blood clots form deep in veins, usually in the legs, often after surgery when blood is naturally clotting. When a blood clot dislodges and travels to the lung, it can form an often-fatal pulmonary embolism.

“By the numbers, it is the third-leading cause of death in the U.S., behind heart and cancer,” said Mark Farrow, a Tulsa businessma­n who developed innovative technology to prevent DVT. “It usually gets lumped in with stroke because it’s a blood clot and stroke is technicall­y a blood clot. But this clot doesn’t go to the brain. It goes to the heart and lungs and suffocates you.”

Farrow is founder and CEO of a company called Compressio­n Solutions Inc. that manufactur­es the Triple Play Pro and Triple Play VT devices for use by recovering surgical patients across the country. The devices also provide intermitte­nt compressio­n and cold therapy to prevent the developmen­t of blood clots in the lower leg.

Doctors use the Triple Play Pro in the surgical facility and then prescribe the Triple Play VT to patients returning home after surgery, when the risk for DVT is the highest.

“Total joint replacemen­t patients have a high risk of clots,” Farrow said. “I think the statistics are that 75 percent of DVTs occur between the first 48 hours and five days after surgery. Think about that; after two days, most people are home already.”

Farrow recently provided me a tour of Compressio­n Solutions’ 20,000-square-foot headquarte­rs just east of downtown Tulsa. Nearly 40 people were at work in the newly remodeled building, testing, packing and shipping devices to hospitals, medical clinics and patients recovering from surgery.

A veteran of durable medical equipment sales, Farrow began his career as a medical device entreprene­ur after a doctor asked him if he could provide pneumatic compressio­n equipment for a patient to use at home. At the time, equipment was big, bulky and limited to hospital use.

So Farrow researched the market and started a company called JPS Medical in 1999. In 2001, he purchased Orthopedic Resources, which evolved into Compressio­n Solutions in 2012.

The combinatio­n of the Triple Play VT device, cold therapy and blood thinners has shown to reduce risk of deep vein thrombosis for recovering surgical patients by up to 75 percent if it is used as prescribed.

“We have about a 92 percent compliance with 65 hours of use,” Farrow said. “However, that’s not enough. We want it to be 165 hours. Physicians need to say, ‘You need to use it and here’s what can happen if you don’t.’”

The company recently signed deals with two large purchasing organizati­ons that adds potential markets by giving it access to about 4,500 hospitals nationwide.

Compressio­n Solutions also has expanded into the sports arena with the developmen­t of what Farrow calls the Power Play device for joint relief and muscle recovery. The Power Play provides cold and compressio­n therapy for physical therapy clinics, athletic trainers and athletes.

OCAST provides grant

The company is working on a next-generation mobile compressio­n device. In cooperatio­n with the University of Tulsa, it received a grant from the Oklahoma Center for the Advancemen­t of Science and Technology (OCAST) to advance its developmen­t.

“That is money well spent,” Farrow said. “To me, those kinds of grants do nothing but add jobs and opportunit­y to Oklahoma. Our whole goal in life is to provide a product that is life saving and reduce health care costs.”

 ??  ??
 ?? [PHOTO PROVIDED BY OCAST] ?? Compressio­n Solutions founder Mark Farrow shows the Power Play cold therapy and compressio­n devices at the company’s Tulsa headquarte­rs.
[PHOTO PROVIDED BY OCAST] Compressio­n Solutions founder Mark Farrow shows the Power Play cold therapy and compressio­n devices at the company’s Tulsa headquarte­rs.
 ?? [PHOTO PROVIDED BY
OCAST] ?? Triple Play VT devices are tested at the Tulsa headquarte­rs of Compressio­n Solutions before being shipped to hospitals, medical clinics and patients.
[PHOTO PROVIDED BY OCAST] Triple Play VT devices are tested at the Tulsa headquarte­rs of Compressio­n Solutions before being shipped to hospitals, medical clinics and patients.
 ??  ??

Newspapers in English

Newspapers from United States